
Maria Aaanesland Dahle
- PhD candidate; MSc
- 22781861
Publications 2026
DNA-Based Biomarkers as Predictors of Carboplatin Response in Neoadjuvant Treatment for Hormone Receptor Positive and Triple-Negative Breast Cancer
Clin Cancer Res (in press)
DOI 10.1158/1078-0432.CCR-26-2212, PubMed 42870529
Publications 2025
High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy
Breast Cancer Res, 27 (1), 143
DOI 10.1186/s13058-025-02092-9, PubMed 40790765
Publications 2024
The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy
Br J Cancer, 131 (10), 1656-1667
DOI 10.1038/s41416-024-02875-5, PubMed 39390250
Publications 2023
In vitro and in vivo characterization of [64Cu][Cu(elesclomol)] as a novel theranostic agent for hypoxic solid tumors
Eur J Nucl Med Mol Imaging, 50 (12), 3576-3588
DOI 10.1007/s00259-023-06310-4, PubMed 37382663